In the context of genetic testing in a woman with breast or ovarian cancer in which a mosaic BRCA1/BRCA2 pathogenic variant is found, it currently remains appropriate to discuss risk management options as for constitutional carriers. The gene discussed is BRCA2; the disease is ovarian carcinoma.